⌕
Vor Biopharma Inc · VOR · Nasdaq
Tenet 51 · Mixed
⇄ Compare
$18.32+0.26 (+1.45%)
Market open · 15-min delayed · as of 2:50 PM ET

Vor Biopharma Inc · Overview

Industry: Drugs · see every company filed here →

Vor Biopharma Inc scores 51/100. Mixed. Strongest on financial health, quality is the soft spot versus 400 Healthcare peers. Insufficient inputs: Tenet 51 is built from 2 of 4 pillars, from 20% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=400
51/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
9
Health
93
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value & Growth omitted — no data yet.
Value—QualityFHealthAGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
no P/E on file
P/B
—
no P/B on file
P/S
—
no P/S on file
ROE
—
negative equity denominator
Operating margin
—
no operating margin on file
Net margin
—
no net margin on file
Current ratio
19.15
Jun 30, 2026 balance sheet
Net debt / EBITDA
—
negative EBITDA denominator
EPS CAGR 5y
—
needs five years of positive earnings
Market cap
$1.1B
small cap
Div yield
0.00%
reinvests all
52-wk range
6.50 – 49.64
low → high

Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).

The whole report, at a glance · every card is a live peek, click any to open the section

Tenets
0 / 17
  • ✕ Piotroski F-Score
  • ✕ Graham Defensive
  • ✕ Quality Compounder
  • ~ Drawdown Context
  • ✕ Reversal Evidence
  • ✕ Not-a-Value-Trap Gate
+11 more →
Financials
Revenue, margins and the five-year statements.
Analyst Forecasts
Consensus estimates are on the Analyst tab.
Earnings
Report dates and the beat-versus-miss record.
Statistics
No ratios yet.
Technical Analysis
Mixed short-term signal
vs 50-day−17.8%
vs 200-day+7.9%
RSI (14)33
News & Insights
Headlines are on the News tab.
Dividends
0.00% yield

Pays no dividend. Every dollar of profit is reinvested into the business.

Ownership
83% institutional

13F flows & insider trades land here.

About Vor Biopharma Inc

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematolog…

Composite computed 2026-10-02 · peer basis: Healthcare (n=400) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

Free account: the funds that hold VOR, and at what weight. Everything else on this page stays open.Create a free account
Methodology© 2026 Tenet Investing Inc. · Toronto, Canada

Data from Intrinio and Financial Modeling Prep.